Aarti Drugs Ltd PE Ratio

Aarti Drugs PE Ratio

Image

Aarti Drugs Ltd

NSE: AARTIDRUGS

PE

16.8

Last updated on: Feb 20, 2026

Key Highlights

  • The P/E Ratio of Aarti Drugs Ltd is 16.8 as of 20 Feb 26 The P/E Ratio of Aarti Drugs Ltd changed from 23.1 on March 2021 to 18.5 on March 2025 . This represents a CAGR of -4.34% over 5 years .

Historical P/E Ratio of Aarti Drugs Ltd

No data available

Company Fundamentals for Aarti Drugs Ltd

Image

Aarti Drugs Ltd

NSE: AARTIDRUGS

Share Price

₹ -

Last updated on: Jan 01, 2026

Market Price of Aarti Drugs Ltd

1M

1Y

3Y

5Y

Monitoring Aarti Drugs Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
20 Feb 2026372.65
19 Feb 2026370.85
18 Feb 2026374.25
17 Feb 2026374.2
16 Feb 2026371.55
13 Feb 2026371.2
12 Feb 2026375.3
11 Feb 2026375.4
10 Feb 2026379.75
09 Feb 2026376.7

SWOT Analysis Of Aarti Drugs Ltd

Strength

2

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Aarti Drugs Ltd

Asset Value vs Market Value of Aarti Drugs Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Key Valuation Metric of Aarti Drugs Ltd

X

Historical Market Cap of Aarti Drugs Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Aarti Drugs Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Aarti Drugs Ltd

No data available

* All values are in %

About Aarti Drugs Ltd

  • Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals.
  • The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million.
  • With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.
  • Company also operates Pinnacle Life Science Private Limited, its wholly owned subsidiary focused on formulation development. The Company has two R&D divisions, one in Tarapur and the other in Turbhe, Maharashtra.
  • It has 3 subsidiaries, namely, Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary).

Aarti Drugs Ltd News Hub

Aarti Drugs hit 52-week high as board OKs Rs 60-cr share buyback

The buyback price fixed at Rs 900 per equity share, representing a 59.66% premium to Friday's closin

Read more

26 Aug 24

Aarti Drugs to consider buyback

Aarti Drugs will hold a meeting of the Board of Directors of the Company on 26 August 2024. Powered

Read more

22 Aug 24

Aarti Drugs soars on share buyback proposal

The announcement was made after market hours yesterday. Aarti Drugs forms part of $6 Billion Aarti G

Read more

22 Aug 24

Board of Aarti Drugs approves buyback of shares up to Rs 59.85 cr

The Board of Aarti Drugs at its meeting held on 26 August 2024 has approved buyback of up to 6,65,00

Read more

26 Aug 24

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions